Document is current
Any future updates will be listed below
-
Authors
Wooten, David J.
Meyer, Christian T.
Lubbock, Alexander L. R. https://orcid.org/0000-0002-6950-8908
Quaranta, Vito https://orcid.org/0000-0001-7491-8672
Lopez, Carlos F. https://orcid.org/0000-0003-3668-7468
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01-CA215845, U54-CA217450)
NSF | BIO | Division of Molecular and Cellular Biosciences (1411482)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | National Institutes of Health (R01-186193)
National Science Foundation (GRFP-1445197)
- License Information
-
More Information
Article History
Received: 26 January 2021
Accepted: 7 July 2021
First Online: 29 July 2021
Competing interests
: C.T.M. and V.Q. are academic founders and part equity holders in Parthenon Therapeutics Inc. All other authors declare no competing interests.
